We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.25
Bid: 10.50
Ask: 12.00
Change: 2.40 (26.67%)
Spread: 1.50 (14.286%)
Open: 9.00
High: 11.40
Low: 9.00
Prev. Close: 9.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

2 Mar 2020 11:45

RNS Number : 6762E
Cantor Fitzgerald Europe
02 March 2020
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Cantor Fitzgerald Europe

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Redx Pharma plc

(d) Date dealing undertaken:

28th February 2020

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

REDX ORD 1P

Purchases

50,000

7.5 GBX

7.5 GBX

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

Nil

Nil

Nil

Nil

Nil

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

Nil

Nil

Nil

Nil

Nil

Nil

Nil

Nil

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

Nil

Nil

Nil

Nil

Nil

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

Nil

Nil

Nil

Nil

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

None

 

 

 

Date of disclosure:

02nd March 2020

Contact name:

Andy Voong

Telephone number:

0207 894 7798

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FERFZGGFGZKGGZM
Date   Source Headline
29th Mar 20167:00 amRNSDirector/PDMR Shareholding
24th Mar 20161:55 pmRNSPlacing to Raise £10 Million
8th Mar 20167:00 amRNSChange of Adviser
24th Feb 201612:39 pmRNSResult of AGM
24th Feb 20167:00 amRNSAGM Statement
22nd Jan 20169:09 amRNSHardman & Co Research Report: Pipeline progress
22nd Jan 20167:30 amRNSHardman & Co Research Report: Pipeline progress
20th Jan 20167:00 amRNSFinal Results
6th Jan 20167:00 amRNSNotice of Results
4th Jan 20167:00 amRNSAppointment of Non-Executive Director
3rd Dec 20157:00 amRNSFourth drug development candidate
10th Nov 20157:00 amRNSRe BioInfect Conference 2015
5th Nov 20157:00 amRNSSenior management appointments
23rd Oct 20152:57 pmRNSRe Review on Antimicrobial Resistance
1st Oct 20157:00 amRNSTrading Update
3rd Sep 20157:00 amRNSCancer Research Collaboration with Redx Pharma
3rd Sep 20157:00 amRNSCancer Research Collaboration
22nd Jun 20157:00 amRNSHalf Yearly Report
19th Jun 20155:14 pmRNSHolding(s) in Company
4th Jun 20159:45 amRNSHolding(s) in Company
2nd Jun 20157:00 amRNSDiscovery of breakthrough MRSA compound
26th May 20157:01 amRNSSecond drug development candidate identified
14th May 20157:00 amRNSRe Review on Antimicrobial Resistance
14th May 20157:00 amRNSLaunch of third subsidiary, Redx Immunology
11th May 20157:00 amRNSPre-Clinical Proof of Concept with Oncology Lead
31st Mar 20155:13 pmRNSHolding(s) in Company
31st Mar 20151:35 pmRNSHolding(s) in Company
31st Mar 20151:33 pmRNSHolding(s) in Company
31st Mar 20159:37 amRNSHolding(s) in Company
27th Mar 20157:00 amRNSAdmission to AIM and First Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.